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A significant proportion of patients with acute stroke symptoms have an alternative “mimic” 
diagnosis. A narrative review was conducted to explore the frequency, characteristics and 
aetiology of stroke mimics. Prehospital and thrombolysis treated patients were described 
separately. 
9,972 studies were identified from the initial search and 79 studies were included with a 
median stroke mimic rate of 19% (range 1-64%). The prehospital median was 27% (range 4-
43%) and the thrombolysis median 10% (range 1-25%).  
Seizures, migraines and psychiatric disorders are the most frequently reported causes of 
stroke mimics. Several characteristics are consistently associated with stroke mimics; 
however, they do not fully exclude the possibility of stroke.  
19% of suspected stroke patients had a mimic condition. Stroke mimics were more common 
with younger age and female gender. The range of mimic diagnoses, a lack of clear 
differentiating characteristics and the short treatment window for ischaemic stroke creates 
challenges for early identification.   
Keywords 
Stroke mimic, narrative review, prehospital, thrombolysis 
 
  





Twenty-six percent of patients with suspected stroke are reported to have a stroke mimic 
(SM)(1) condition as the final diagnosis, which reflects the challenging nature of clinical 
diagnosis. In order to maximize prehospital identification of stroke patients, assessment 
tools (2-4) focus upon positive identification of common stroke symptoms (sensitivity) at the 
expense of specificity, and so contribute further towards the high rate of SM (4). Failure to 
identify SM patients could lead to inappropriate treatment and inefficient use of specialist 
stroke services. This might be most important in centralised service configurations (5, 6)  
where prehospital suspected stroke cases bypass local hospitals, thereby increasing 
ambulance transfer times for SM patients and displacing them from appropriate local care.  
Even with specialist input and improving access to neuroimaging, SM patients receive 
thrombolysis (7). Due to the time dependent nature of thrombolysis, the limited availability 
of advanced imaging and the low risk of intracerebral haemorrhage amongst SM patients (8, 
9) current practice favours treatment of eligible suspected stroke patients due to the 
perceived risk benefit balance. 
A number of studies have developed tools to identify SM (10-12). These tools use 
characteristics associated with SM diagnosis, such as patient age or presence of seizures, 
along with the absence of factors associated with stroke diagnosis, such as atrial fibrillation 
or hypertension.  
This narrative review was conducted to summarise the literature describing SM frequency, 
characteristics and aetiology and explore the issues relating to identifying SM patients at an 
early stage.  





A systematic search was performed with the results reported using narrative synthesis. The 
review protocol was prospectively registered on PROSPERO registration number 
42015026457 (13). This review is reported following the PRISMA statement (14).  
Inclusion criteria 
To be eligible for inclusion studies had to fulfil the following criteria: 
 Primary studies describing adult (18 years and above) patients with initial diagnosis 
of stroke and final non-stroke diagnosis 
 Reported a number and/or rate of SM  
 Reported the clinical and/or demographic characteristics of a SM population 
 Published in the English language 
Case reports were excluded from the review. 
Database search strategy 
A simple but structured search strategy (supplemental digital content 1) was developed with 
input from an information specialist. This was applied to the following databases up to 
February 2017: MEDLINE; EMBASE; PsycInfo; CINAHL; Cochrane Database of Systematic 
Reviews and Database Of Research In Stroke. Grey literature was identified using the first 30 
pages of Google and Google Scholar (15).  
Study selection process 
Studies were screened based upon title and abstract by one reviewer (GM) with 
uncertainties discussed with another member of the review team. Abstracts which 




appeared relevant were assessed for eligibility in full text format by the same reviewer 
(GM). The reference lists of all studies included were hand searched. Citation searching of 
included studies was undertaken using ISI Web of Science.  
Data extraction and analysis 
Data were extracted using a structured form to capture the following: title; authors(s); 
journal; year; country; setting; proportion of SM; stroke assessment tool; method of stroke 
diagnosis; method of SM diagnosis; presence of SM final diagnosis; demographics or clinical 
characteristics.  
Clinical Classification Software (CCS) codes were used to combine SM diagnoses reported 
within studies using variable terminology into clinically relevant groups (16).  
Due to the descriptive aims of the review, variability in the definition of stroke and SM and 
the anticipated heterogeneity of studies with variable quality there was no pre-specified 
meta-analysis.  
Quality assessment 
Due to anticipated heterogeneity within the literature the QATSDD tool for reviewing 
studies with diverse designs was preselected for assessing study quality (17). This tool was 
not applied to abstracts.  





The search strategy yielded 9,972 references (Figure 1). After initial screening 336 full text 
articles were reviewed.  
 
Seventy-nine studies (full details and references in supplemental digital content 2) were 
included in the review. 
The median year of publication was 2013 (range 1982-2017). The majority of studies 
originated from North America (n=34, 43%) or Europe (n=29, 37%). The majority (n=78, 
99%) of studies were cohort studies with 41 (53%) collecting data prospectively, 36 (46%) 
retrospectively and in 1 (1%) study the direction of data collection was unclear. 
The overall population include 147,779 patients. SM patients were younger than stroke 
patients (pooled mean age 61.7 vs 69.6 years) with a higher percentage of females (pooled 
female gender 53.3% vs 47.7%). Included studies were described as three groups. Those 
with populations confined to prehospital settings (n=7) reflect the early identification of 




suspected stroke patients, usually through application of specific tools and protocols. 
Thrombolysis studies (n=21) are separately described as these have a clearly defined sub-
population based upon the criteria for administration of a specific treatment. All other 
studies (n=51) were not uniquely prehospital or thrombolysis focussed. 
The pooled mean and median SM rates were 22% (SD 16%) and 19% (IQR 9.5-33%) 
respectively. The median SM rates were 27% (IQR 13-38.5%) in the general group, 27% (IQR 
16-37%) in the prehospital group and 10% (IQR 2.5-14%) in the thrombolysis group. These 
SM rates are summarised in figure 2. 
 
QATSDD scoring was converted into an overall percentage for each study to simplify 
comparison. Included studies scored a median 60% (IQR 52-69) on the QATSDD (see 
supplemental digital content 3). The three subgroups had similar pooled mean scores on the 
QATSDD: prehospital 64%; mixed 59% and thrombolysis 59%. As a sensitivity analysis the 
studies scoring below the lower QATSDD quartile were compared with studies scoring above 




the upper quartile. The lowest quartile studies (n=17) reported a pooled mean SM rate of 
21% (SD 17.5) based on 5,601 patients and the highest quartile studies (n=11) reported a 
pooled mean SM rate of 28% (15.1) based on 6,680 patients.  
Stroke mimic final diagnosis 
Sixty-three studies (80%) reported the SM underlying diagnoses. Methods of identifying the 
diagnosis of SM included: discharge/final diagnosis (40%); neurologist or stroke specialist 
assessment (17%); expert panel (14%); registry (6%); and other/unclear (22%).  
SM diagnoses were summarised using CCS codes.(16) This resulted in 103 initial CCS codes, 
which were reported using level 1 CCS (broad disease categories) and level 2 CCS (more 
specific disease areas) codes (Figure 3).  
 
Figure 3. Taxonomy of stroke mimics using Clinical Classification Software (CCS) codes. 
Prehospital 




Seven (9%) studies clearly described prehospital settings: 6,870 patients, mean SM rate 26% 
(SD 14%). SM patients were younger than stroke (67 vs 73 years pooled mean age) with a 
higher proportion of females (SM 58% female vs stroke 49% female).  
The most frequent level 1 CCS diagnostic groups in the pure prehospital setting were: 
diseases of the nervous system and sense organs (29%); symptoms, signs and ill-defined 
conditions and factors influencing health status (9%) and unknown (43%). The most 
frequent level 2 CCS diagnostic groups were: epilepsy and convulsions (19%); symptoms, 
signs and ill-defined conditions (9%) and ear conditions (5%). 
Thrombolysis 
Twenty-one (26%) studies described SM in patients treated with thrombolysis: 103,731 
patients, mean SM rate 9% (SD 7%). SM patients were younger than stroke patients (57 vs 
68 years mean age). More SM patients were female (SM pooled mean 57% vs stroke 46%). 
The most frequent level 1 CCS diagnostic groups in the thrombolysis cohorts were: diseases 
of the nervous system and sense organs (37%); mental illness (18%) and unknown (42%). 
The most frequent level 2 CCS diagnostic groups were: miscellaneous mental disorders 
(17%); headache including migraine (17%); and epilepsy and convulsions (16%). 
General studies 
Fifty-one (65%) studies described cohorts that were not specifically identified as pre-
hospital or receiving thrombolysis: 37,178 patients, mean SM rate 27% (SD 16%). These 
settings included: hospital (41%); Emergency Department (ED) (35%); stroke unit/hyper 
acute stroke unit (HASU) (18%); telemedicine (4%); and general practice (2%). The total 
population was 50% male with a pooled mean age of 68 years. SM patients were younger 




than stroke (63 vs 70 years pooled mean age) with a higher proportion of females (SM 51% 
female vs stroke 48% female). 
The most frequent level 1 CCS diagnostic groups were: diseases of the nervous system and 
sense organs (34%); diseases of the circulatory system (15%); mental illness (10%) and 
unknown (17%). The most frequent level 2 CCS diagnostic groups were: epilepsy and 
convulsions (10%); cerebrovascular disease e.g. transient ischemic attack; subdural 
haemorrhage (9%); and headache including migraine (9%). 
Clinical characteristics 
Studies reporting clinical characteristics associated with SM are described in table 2 (see 
supplemental digital content 4 for table with references). Associations between clinical 
characteristics and diagnosis were reported as positive for SM or stroke (p<0.05 or stated 
within text as significant) or non-significant.  
  




Table 2. Number of studies reporting characteristics associated with stroke mimic diagnoses  
  Characteristics  
Associated 








Past medical history 
Diabetes 2 (6%)  23 (68%) 9 (26%) 
Hypercholesterolemia 3 (27%) 6 (55%) 2 (18%) 
Migraine 5 (71%) 2 (29%) 0 
Seizure 9 (75%) 3 (25%) 0 
Smoker 1 (4%) 21 (81%) 4 (15%) 
Stroke 7 (29%) 12 (50%) 5 (21%) 
Transient Ischemic Attack (TIA) 1 (25%) 2 (50%) 1 (25%) 
Symptoms (negative) 
Abnormal admission neurological 
examination 1 (100%) 0 0 
Altered level of consciousness / 
mental status 9 (60%) 5 (33%) 1 (7%) 
Aphasia 1 (50%) 0 1 (50%) 
Cognitive impairment 3 (75%) 1 (25%) 0 
Confusion 3 (75%) 1 (25%) 0 
Dysphagia 1 (100%) 0 0 
General weakness 1 (100%) 0 0 
Sensory deficit 4 (100%) 0 0 
Symptoms (positive) 
Diabetic symptoms 1 (100%) 0 0 
Dizziness / vertigo 5 (63%) 3 (38%) 0 
Headache 1 (14%) 5 (71%) 1 (14%) 
Pain 1 (100%) 0 0 
Psychiatric / somatic disorder 6 (86%) 1 (14%) 0 
Seizure 6 (100%) 0 0 





Can walk now 1 (100%) 0 0 
Neuro symptoms inconsistent with 
vascular territory 1 (100%) 0 0 
No lateralising symptoms 1 (100%) 0 0 
No motor or speech deficit 1 (100%) 0 0 
No neurological signs 1 (100%) 0 0 
Normal extraocular movements 1 (100%) 0 0 
Normal Glasgow Coma Score 1 (100%) 0 0 
 
  





This review identified SM studies with heterogeneous aims, settings and reporting methods. 
The studies included had a wide range of QATSDD scores, however the subgroup mean 
scores were similar. As there were no pre-specified exclusion criteria based on quality 
assessment all identified studies were included. The QATSDD identified that very few 
studies discussed sample size or considered the accuracy of the final diagnoses therefore an 
element of selection bias must be acknowledged.  
Our findings build on earlier work (1) by showing that despite advancing technology and 
better availability of specialist assessment, SM continues to be a diagnostic challenge. To 
inform the development of screening processes with improved specificity, we have 
described typical characteristics that may aid with SM diagnosis and discuss tools that have 
been developed to aid identification. 
Frequency 
The reported rate of SM was influenced by the clinical definition of stroke used at the time 
of the study and therefore varied across the literature (18). SM accounted for 22% of all 
suspected stroke cases, which is lower than 26% previously reported (1). This discrepancy 
may be the result of recent large thrombolysis cohorts being included (7, 19). Thrombolysis 
studies have a lower SM frequency because of the specialist assessment, treatment criteria 
and neuroimaging required to make treatment decisions. However, the pooled SM rate for 
prehospital and general populations was similar at 27%. Studies in the upper quartile based 
on QATSDD scoring reported a higher SM rate (28%) than studies in the lower quartile (21%) 
so the combined figure may be an under-estimate. 




The high frequency of SM in prehospital care may be due to a number of factors: most 
prehospital services are paramedic led; application of high sensitivity stroke identification 
instruments; availability of information about past medical history; and the lack of imaging. 
Nevertheless, SM rates were similar in prehospital and hospital groups. This may reflect that 
a significant portion of the general group were also unfiltered prehospital patients, and that 
the initial diagnosis made in the prehospital setting is not over-ruled until later stroke 
specialist assessment and brain imaging.   
The presence of SM in thrombolysis populations reflects the challenging nature of acute 
stroke treatment. The drive to reduce door-to-needle (DTN) time may be linked with 
increased SM thrombolysis (20). Thrombolysing SM has relatively low risks (19, 20) but does 
have financial implications (21). Using current diagnostic processes this is a challenging area 
to address because of the lack of clear clinical characteristics differentiating stroke from SM; 
and the need to treat patients early to get the most benefit. Developments and investment 
in rapid advanced imaging to reveal positive evidence of acute ischaemia would help avoid 
thrombolysis for some patients in this group (22).    
Characteristics 
SM patients tended to be younger than stroke patients and were more likely to be female. 
The mean age falls as patients move from prehospital care, to non-specialist care (general 
group) and on to specialist care (thrombolysis group). This may reflect the increasing rigour 
of the assessment process. 
Clinical characteristics (Table 2) were reported under a variety of overlapping terms. Due to 
methodological concerns we did not create a weighted average or conduct a meta-analysis. 
The distribution of clinical characteristics across studies was used as a crude measure of 




association. Seizures, history of migraine and psychiatric disorders were the characteristics 
with the clearest association with SM diagnosis. There was disagreement between studies 
as to the direction of association for some characteristics e.g. history of stroke is associated 
with stroke (5 studies), SM (7 studies) and non-significant (12 studies). This reflects that 
although vascular risk factors are more likely to be present amongst stroke patients, their 
presence was a reason for clinicians to wrongly suspect stroke as a cause for new 
symptoms. However as a stronger risk factor, AF had a clearer relationship with stroke (26 
studies positive association; 7 non-significant association).  
Focal neurological deficits used by most identification scores maintained their relationship 
with stroke e.g. facial palsy/weakness (1 non-significant, 13 associated with stroke)(23, 24). 
The absence of these characteristics could be an indicator of SM, and has been used in SM 
identification tools (10).  
Aetiology 
Many conditions present as SM and diagnostic methods, including the use of brain imaging, 
were highly variable in the literature. The definition of stroke, and therefore SM, varied and 
conditions such as TIA and sub-arachnoid haemorrhage were variably classified as stroke or 
SM. It is important that investigators transparently present data so that services can decide 
upon the relevance of the results.  
The use of CCS codes allowed the findings of this heterogeneous dataset to be summarised. 
Disorders of the nervous system and sense organs were the most common cause of SM, 
particularly seizures which mirrors previous findings (1). Some prehospital stroke tools used 
seizures to indicate a reduced likelihood of stroke (3, 25) and some SM identification tools 
also included seizures (10, 11). Accurate history taking is crucial, but seizures can be 




unwitnessed and it is only the gradual recovery, lack of acute changes on imaging, 
clarification of previous medical history and further investigations which reveal the 
diagnosis. As 2% of acute stroke patients experience a seizure (26), this is an area where 
development of rapid diagnostics may be helpful.   
Clinical implications 
Although SM have short stays on HASUs (mean 2.8 days), the frequency of SM admissions 
accounts for 8-17% of HASU bed occupancy, which could be otherwise used treating stroke 
patients (27). Prehospital identification of SM may help to ensure that patients access 
appropriate pathways of care, especially in centralised service configurations which require 
a prehospital redirection decision.  
Application of a SM identification tool, such as those described earlier (10-12), would 
support creation and evaluation of a two stage process. The initial stage is suspicion of 
stroke based on triggering a high sensitivity tool at dispatch (28) and/or during clinical 
assessment such as FAST(2), and the second stage is refinement of this initial diagnosis 
based upon a SM assessment with high specificity. This two stage assessment does not 
include the initial suspicion of stroke by the ambulance dispatch centre where high 
sensitivity to potential stroke is paramount. A recent study using CPSS guided dispatch of 
ambulances was able to identify 2/3 of patients suitable for thrombolysis simply through 
structured telephone description of symptoms (28), but there is currently no formalised 
prehospital equivalent score at dispatch to then identify patients who could be a SM. 
Due to the lack of clinical characteristics that clearly differentiate strokes and SM, this 
second stage provides an opportunity to apply novel point of care diagnostic technologies 
(29, 30) to improve the overall assessment performance. A SM assessment could also be 




used to help target specialist resources such as mobile stroke units (31). These may also 
assist in an early decision about whether patients being assessed for thrombolysis should 
have additional imaging, other than CT, in order to minimize inappropriate treatment, 
particularly as migraine was more common amongst the thrombolysis SM population.  
In the meantime, clinician knowledge of common SM characteristics could inform the 
differential diagnoses considered when assessing suspected stroke patients. Training 
programmes should encourage clinicians to seek additional information which might 
broaden the diagnosis for key demographic groups.  
Limitations 
Meta-analysis was not attempted due to the narrative nature of this review and study 
heterogeneity. A quality assessment tool tailored for cohort studies may have been more 
appropriate than the QATSDD tool which was chosen prior to study identification. The initial 
screening and identification was performed by a single reviewer so relevant studies could 
have been missed. We did not include non-English studies. CCS coding simplified cases to a 
single diagnostic category to aid reporting, but this does not represent the multiple 
problems some patients possess. The prehospital population was small reflecting the lack of 
clearly described prehospital research. The representation of clinical characteristics is crude 
but could be used to inform the focus of future studies. 
Conclusion 
Twenty-two percent of all suspected stroke patients had a SM condition. SM patients 
included a higher proportion of females and tended to be younger than stroke patients. 
Many conditions present as SM but seizures and migraines are the most frequent 




aetiologies. It is challenging to identify clinically useful characteristics that differentiate SM 
from stroke, however a combination of stroke and SM assessment tools during the acute 
phase of emergency stroke care might reduce the number of false positive identifications 
created by commonly used symptom checklists.  
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